Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Abstract

Felodipine is a vascular-selective, dihydropyridine calcium antagonist previously investigated as a conventional tablet formulation administered twice daily. More recently considerable experience has been gained with an extended release (ER) formulation which has the convenience of once daily administration. Felodipine ER has been well studied in patients with essential hypertension. As monotherapy in mild to moderate essential hypertension, felodipine ER is at least as effective in reducing blood pressure as other calcium antagonists, beta-blockers, diuretics and ACE inhibitors, with some results favouring felodipine ER at a statistically significant level at the dosages used. It is also effective combined with controlled release metoprolol or enalapril in patients with mild to moderate essential hypertension. In patients with more severe forms of essential hypertension uncontrolled by beta-blocker and/or diuretic therapy, felodipine ER was effective as an 'add-on' therapy in placebo-controlled trials, and, at the dosages used, more effective than either sustained release nifedipine or nitrendipine. Felodipine produces effective control of blood pressure without negative effects on cardiac performance. In addition to its antihypertensive action, results suggest that felodipine therapy is associated with significant regression of left ventricular hypertrophy. Furthermore, it appears suitable for use in patients with concomitant diabetes, renal dysfunction or asthma, and is also being investigated for use in patients with congestive heart failure or angina pectoris. Felodipine ER is an effective drug for the treatment of all grades of essential hypertension, and can be used both as monotherapy and in combination with other antihypertensive agents. Further clinical experience should fully establish the long term tolerability of felodipine ER and consequently its place in therapy relative to other accepted antihypertensive drugs. However, with the convenience of once daily administration, felodipine ER is a worthwhile innovation in the treatment of hypertension.

• Authors: P A Todd, D Faulds
• Journal: Drugs (Drugs) Vol. 44 Issue 2 Pg. 251-77 (Aug 1992) ISSN: 0012-6667 [Print] New Zealand
• PMID: 1382018 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Review)

Chemical References

• Delayed-Action Preparations
• Felodipine

Topics

• Angina Pectoris (drug therapy)
• Cardiomegaly (complications, drug therapy)
• Delayed-Action Preparations
• Diabetes Mellitus, Type 2 (complications)
• Drug Interactions
• Drug Therapy, Combination
• Felodipine (administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
• Heart Failure (drug therapy)
• Humans
• Hypertension (complications, drug therapy)